» Articles » PMID: 35016569

Prevalence, Pattern, Risks Factors and Consequences of Antibiotic Resistance in COPD: A Systematic Review

Overview
Journal COPD
Publisher Informa Healthcare
Specialty Pulmonary Medicine
Date 2022 Jan 12
PMID 35016569
Authors
Affiliations
Soon will be listed here.
Abstract

A concern of antibiotic use in chronic obstructive pulmonary disease (COPD) is the emergence and propagation of antimicrobial resistance (AMR). A systematic review was conducted to determine prevalence, pattern, risk factors and consequences of AMR in COPD. Bibliographic databases were searched from inception to November 2020, with no language restrictions, including studies of any design that included patients with COPD and reported prevalence and pattern of AMR. 2748 unique titles and abstracts were identified, of which 63 articles, comprising 26,387 patients, met inclusion criteria. Forty-four (69.8%) studies were performed during acute exacerbation. The median prevalence of AMR ranged from 0-100% for and . Median resistance rates of and were lower by comparison, with maximum rates ≤40% and ≤46%, respectively, and higher for . There was a trend towards higher rates of AMR in patients with poorer lung function and greater incidence of previous antibiotic exposure and hospitalisation. The impact of AMR on mortality was unclear. Data regarding antimicrobial susceptibility testing techniques and the impact of other risk factors or consequences of AMR were variable or not reported. This is the first review to systematically unify data regarding AMR in COPD. AMR is relatively common and strategies to optimise antibiotic use could be valuable to prevent the currently under-investigated potential adverse consequences of AMR.Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.2000957 .

Citing Articles

Molecular screening and dynamics simulation reveal potential phytocompounds in Swertia chirayita targeting the UspA1 protein of Moraxella catarrhalis for COPD therapy.

Uddin M, Chowdhury M, Hossain M, Ahsan A, Hossain M, Barik A PLoS One. 2025; 20(2):e0316275.

PMID: 40019889 PMC: 11870343. DOI: 10.1371/journal.pone.0316275.


Healthcare worker views on antimicrobial resistance in chronic respiratory disease.

Ananth S, Adeoti A, Ray A, Middleton P, Ekkelenkamp M, Thee S Antimicrob Resist Infect Control. 2025; 14(1):1.

PMID: 39844291 PMC: 11752958. DOI: 10.1186/s13756-025-01515-8.


Efficacy of Prophylactic Antibiotics in COPD: A Systematic Review.

Tran A, Ghanem A, More M, Nagy A, Toth A Antibiotics (Basel). 2025; 13(12.

PMID: 39766500 PMC: 11672715. DOI: 10.3390/antibiotics13121110.


Development and validation of a nomogram for predicting bacterial infections in patients with acute exacerbation of chronic obstructive pulmonary disease.

Wang X, Yuan W, Zhong D, Chen X Exp Ther Med. 2024; 29(1):3.

PMID: 39534283 PMC: 11552094. DOI: 10.3892/etm.2024.12753.


Spectrum and antimicrobial resistance in acute exacerbation of chronic obstructive pulmonary disease with pneumonia: a cross-sectional prospective study from Vietnam.

Dao D, Le H, Nguyen M, Thi T, Nguyen X, Bui T BMC Infect Dis. 2024; 24(1):622.

PMID: 38910264 PMC: 11194910. DOI: 10.1186/s12879-024-09515-6.